Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). We also have additional preclinical stage programs, including the Middle East Respiratory Syndrome coronavirus (MERS). Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Company Growth (employees)
Gaithersburg, US
Size (employees)
355 (est)
Novavax was founded in 1987 and is headquartered in Gaithersburg, US

Novavax Office Locations

Novavax has offices in Gaithersburg, Rockville and Uppsala
Gaithersburg, US (HQ)
20 Firstfield Rd
Uppsala, SE
109 Kungsgatan
Rockville, US
9920 Belward Campus Dr

Novavax Financials and Metrics

Novavax Financials

Novavax's revenue was reported to be $5.7 m in Q1, 2017

Revenue (Q1, 2017)

5.7 m

Net income (Q1, 2017)

(43.9 m)

EBIT (Q1, 2017)

(40.8 m)

Market capitalization (12-Oct-2017)

334.5 m

Cash (31-Mar-2017)

95.8 m
Novavax's current market capitalization is $334.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


20.9 m30.7 m36.3 m15.4 m

Revenue growth, %


R&D expense

50.3 m79.4 m162.6 m237.9 m

General and administrative expense

14.8 m19.9 m30.8 m46.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


8.3 m8.2 m9.9 m14 m6.5 m4.2 m2.5 m3.2 m5.7 m

R&D expense

15.2 m19.2 m25.9 m25 m27.9 m69 m64.9 m53 m37.7 m

General and administrative expense

5.8 m4.8 m5.8 m7.1 m9.1 m10.5 m14.1 m13.6 m8.9 m

Operating expense total

21 m24 m31.7 m32.1 m37 m79.5 m79 m66.5 m46.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


119.5 m32.3 m93.1 m144.4 m

Accounts Receivable

1.9 m7.5 m2.3 m233 k


9.2 m19.3 m21.8 m

Current Assets

145 m188.2 m287.3 m287.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


103.9 m34.5 m215.1 m167.4 m138.1 m132.2 m89.4 m119.9 m95.8 m

Accounts Receivable

406 k363 k591 k

Current Assets

166.6 m192 m350.1 m333 m310.1 m484.6 m420 m353.9 m258.4 m


15.1 m17.5 m24 m26.1 m29.4 m36.6 m39.7 m41 m39.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(52 m)(82.9 m)(156.9 m)(280 m)

Depreciation and Amortization

2.6 m4.4 m6 m8.5 m

Accounts Receivable

2.1 m

Accounts Payable

4.2 m14 m9.1 m(4.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(31.7 m)(51.4 m)(24.4 m)(45 m)(78.1 m)(77.3 m)(156.6 m)(222.9 m)(43.9 m)

Depreciation and Amortization

2 m3 m1.3 m2.8 m4.3 m2 m4.1 m6.3 m2.1 m

Accounts Receivable

1.9 m2 m1.7 m

Accounts Payable

(1.3 m)(164 k)(7.6 m)(8.3 m)(7.7 m)1.5 m9 m6.4 m(4.9 m)
USDY, 2017


16 k
Show all financial metrics

Novavax Operating Metrics

FY, 2016

Patents (US)


Phase II Trials


Phase III Trials


Phase I Trials

Show all operating metrics

Novavax Market Value History

Novavax Median Salaries

Source: 30 public H-1B filings from Novavax

Traffic Overview of Novavax

Novavax Online and Social Media Presence

Novavax News and Updates

Merck's Ebola vaccine candidate could see early action against new Congo outbreak

​​​​​​​Merck & Co. and other biopharma players hustled to develop Ebola vaccines amid a devastating West Africa epidemic that started in 2014. Now, before Merck’s shot wins an official license, it could be used to combat a new outbreak in Congo.

Novavax Company Life and Culture

You may also be interested in